Can PVSRIPO Rekindle Antitumor Responses in the PD-1/L1 Tefractory Population?
North Carolina-based Istari Oncology, Inc. announced that the first patient was dosed in the LUMINOS-102 phase 2 clinical trial, which will assess the safety and efficacy of PVSRIPO alone or in combination with a programmed death receptor-1/ligand 1 (PD-1/L1) inhibitor in patients with melanoma who are resistant to these checkpoint therapies.
PVSRIPO is a novel viral immunotherapy that activates the innate and adaptive immune system to stimulate the production of a functional, systemic anticancer CD8+ T cell response.
“Anti-PD-1/L1 therapies have been a major advancement in melanoma treatment, however, many patients develop resistance or never respond in the first place,” said Matt Stober, President, and CEO at Istari Oncology, in a related press statement.
“We are very optimistic about the prospects for the phase 2 trial. PVSRIPO monotherapy has already shown clinical activity in this population, and its mechanism is synergistic with anti-PD-1/L1 therapies, so we believe the combination may provide even more benefit.”
Following positive phase 1 results, the phase 2 trial will further explore PVSRIPO’s impact on this population of patients in severe need of additional therapeutic options.